Filing Details

Accession Number:
0001209191-21-040324
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-14 18:18:31
Reporting Period:
2021-06-11
Accepted Time:
2021-06-14 18:18:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1661460 Poseida Therapeutics Inc. PSTX Biological Products, (No Disgnostic Substances) (2836) 472846548
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1766302 A. Matthew Spear C/O Poseida Therapeutics, Inc.
9390 Towne Centre Drive, Ste 200
San Diego CA 92121
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-11 4,000 $1.32 20,485 No 4 M Direct
Common Stock Disposition 2021-06-11 4,000 $9.44 16,485 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-06-11 4,000 $0.00 4,000 $1.32
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
119,861 2026-06-19 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.55 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within therange set forth in this footnote.
  3. The stock option is fully vested and exercisable.